romiplostim + ciclosporin A

A combination therapy of **romiplostim** and **ciclosporin A** used primarily for the treatment of hematological disorders, especially severe or refractory immune thrombocytopenia (ITP) and aplastic anaemia. Romiplostim is a thrombopoietin receptor agonist (TPO-RA) that stimulates platelet production by activating the thrombopoietin receptor (c-Mpl) on megakaryocyte precursors, leading to increased platelet counts. Ciclosporin A is an immunosuppressant that inhibits T-cell activation via calcineurin inhibition, thereby modulating immune responses. This combination targets multiple underlying mechanisms: boosting platelet production (romiplostim) and suppressing the immune-mediated destruction of platelets (ciclosporin A), and has been evaluated in settings where monotherapy proved insufficient[3][1][2].